BioSpace News Archive

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced positive results from its good laboratory practice (GLP) preclinical toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its proprietary bioerodible Durasert® technology for wet age-related macular degeneration (wet AMD).

Protara Therapeutics, Inc. announced the grants of inducement non-qualified stock options to purchase an aggregate of 41,500 shares of common stock to two new employees.

This transaction will be immediately accretive to the Company adding complementary services and insurable revenue to the existing primary care model across 15 States.

TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 62nd American Society of Hematology (ASH) annual meeting and exposition, to be held virtually December 5 – 8, 2020.

Nevro Corp. (“Nevro”) (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced that Susan E. Siegel has been appointed as a member of the Board of Directors (the “Board”), effective December 2, 2020.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced it has submitted new drug applications (“NDA(s)”) for XPOVIO®

The Lennox-Gastaut Syndrome (LGS) Foundation is pleased to announce that Dr. Tracy Dixon-Salazar is now the new Executive Director of the LGS Foundation.

A randomized controlled trial demonstrated 70% lower 30-day readmissions and 40% care cost reduction compared with usual hospital care

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Department of Veterans Affairs (VA) has awarded the Company a contract for the purchase of Phexxi® (lactic acid, citric acid and potassium bitartrate) for a five-year period beginning December 15, 2020.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab